Proteostasis Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference
Cambridge, Mass., September 10, 2012 — Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with neurodegenerative and orphan diseases, announced today that it will present at the Rodman & Renshaw 14th Annual Healthcare Conference on Tuesday, September 11, 2012 from 12:05 p.m. ET to 12:30 p.m. ET in New York, NY.
About Proteostasis Therapeutics
Proteostasis Therapeutics is developing disease-modifying therapeutics for orphan and neurodegenerative diseases. The Company’s lead programs in Cystic Fibrosis (CF) and protein aggregation disorders such as Parkinson’s disease modulate protein chaperone and proteasomal degradation pathways within the cell. These pathways are part of the cellular ‘quality control’ machinery, called the protein homeostasis network or Proteostasis Network (PN) that regulates protein folding, trafficking, and clearance. By enhancing the function and capacity of the PN, the Company’s product candidates correct for imbalances in the PN resulting from the cumulative effects of disease, genetic mutations, environmental factors, and aging. For more information, please visit www.proteostasis.com.
Stern Investor Relations, Inc.